Zelboraf Approved for Rare Blood Cancer

MONDAY, Nov. 6, 2017 — Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat Erdheim-Chester Disease, a rare but deadly blood cancer. The approval covers patients who have a genetic mutation…
Source: Topamax